Polyinosinic acid used as a model RNA, is composed of a polynucleotide chain. It consists entirely of inosinic acid residues. Polyinosinic acid is made from polycytidylic acid. It is a homopolymer of inosine used with polycytidylic acid to form a double stranded homopolymer. This acts as a major effector of the immune response against viral pathogens. Polyinosinic acid is primarily used in the form of sodium salt to simulate viral infections.
Request
PDF brochure
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22208
Polyinosinic
acid (abbreviated as Poly I:C) along with polycytidylic acid acts as an
immunostimulant. It is known to interact with toll-like receptor 3, which is
expressed in the membrane of B-cells, macrophages, and dendritic cells.
Polyinosinic acid enhances delivery of adenovirus vectors. It is used primarily
in pharmaceuticals, health care, and medical sectors. Polyinosinic acid is
employed as a potent adjuvant in the medical sector to enhance the specific
anti-tumor immune responses against a peptide-based vaccine. Growth in
pharmaceutical and health care sectors is expected to boost the demand for
polyinosinic acid in the next few years.
More
Trending Reports
Polyinosinic acid is anticipated to penetrate the market rapidly
due to the various research and development activities conducted by several
companies and medical organizations. It is not available widely since it is
medical product; however, demand for polyinosinic acid is high due to its
anti-tumor immune responses. Polyinosinic acid requires ionic strength to
maintain the double strand structure. In order to prevent denaturation,
polyinosinic acid is reconstituted in solutions with physiological salt
concentrations. Furthermore, it may require heating and cooling to achieve
re-annealing.
Asia
Pacific held the major share of the polyinosinic
acid market in 2015, led by the high growth of pharmaceutical and
medical sectors. Demand for polyinosinic acid is also high in Europe and North
America. The U.S., Germany, China, India, and Japan accounted for key share of
the polyinosinic market in 2015. Polyinosinic acid is highly produced and
consumed in these countries due to the increase in population, high standard of
living, rise in number of diseases among the people, and expansion in
pharmaceutical and medical sectors. Middle East & Africa constituted
smaller share of the polyinosinic market in 2015; however, demand for
polyinosinic acid is anticipated to rise at a rapid pace in the region in the
next few years. Optimization of physicochemical properties of polyinosinic acid
has led to generation of derivatives that have increased stability in body
fluids (such as polyICLC), or reduced toxicity through reduced stability in
body fluids. This is estimated to boost the polyinosinic acid market during the
forecast period.
Request
enquiry before buying
https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=22208
Key
manufacturers of polyinosinic acid across the globe include Biotain Pharma Co.
Ltd., N&R Bio Industries Inc., Beijing Isomersyn Technology Co. Ltd., Hubei
XinyuanShun Chemical Co. Ltd., and Hangzhou Dingyan Chem. Co. Ltd.
Request for custom research
https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=22208
Comments
Post a Comment